Director, Global Value Access & Pricing NSCLC

Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide.

Our people are united by a shared way of working: follow the science, challenge assumptions, act with urgency and hold ourselves to a high standard of rigor—all in service of patients.

The Director, Global Value, Access & Pricing – NSCLC develops and drives execution of global value, access, and pricing strategies for assigned NSCLC assets and indications. The role ensures payer, HTA, pricing, and evidence requirements inform clinical development, launch preparation, and lifecycle planning to enable timely, sustainable patient access across priority markets.

The Director serves as a core global GVAP lead on cross-functional teams, translating strategy into evidence, pricing, and launch plans. The role partners closely with HEOR, Clinical Development, Regulatory, Commercial, Finance, Medical Affairs, and Regional Market Access to align global and regional execution.

• Develop and drive implementation of global value, access, and pricing strategies for assigned NSCLC assets and indications, including launch sequencing, pricing architecture, reference pricing considerations, and net price corridor management across priority markets.
• Lead development of the global value story and payer evidence requirements for assigned NSCLC assets, partnering with HEOR on evidence plans, evidence-gap assessments, and early-advice preparation.
• Assess NSCLC competitive dynamics, including line-of-therapy positioning, biomarker-driven access and companion-diagnostic testing considerations, and combination-therapy reimbursement implications.
• Lead cross-functional EU Joint Clinical Assessment (JCA) readiness activities, aligned with global JCA strategy and in collaboration with regional Market Access and HEOR teams.
• Build and maintain strong relationships with Clinical, Commercial, Regulatory, HEOR, and Medical Affairs functions.
• Partner with regional teams on local pricing, reimbursement, and negotiation readiness; synthesize regional insights and risks for global decision-making.
• Provide market access input into clinical development programs to optimize endpoints, comparators, and evidence packages for payer and HTA success.
• Provide access and pricing analyses and recommendations to lifecycle planning and business development evaluations.

• Bachelor’s degree required; advanced degree Ph.D., PharmD, MD, or MSc in Health Economics, Public Health, Health Policy, or a related field preferred.
• 10+ years of relevant experience in market access and pricing, including significant global and/or major-market responsibility.
• Strong experience in pricing & reimbursement of oncology products.
• Deep understanding of global payer systems and HTA processes across Europe (e.g., NICE and G-BA/AMNOG), Japan, and the United States.
• Experience designing and implementing global pricing strategy, including value-based pricing, launch sequencing, and reference pricing mitigation.
• Experience with pricing regulations, early pricing analysis, and partnering with affiliates on pricing and reimbursement negotiations.
• Demonstrated ability to support clinical development to…